Friday, 16 October 2026European Markets

ESI GROUP Stock Over 34% Up In The Last 21 Sessions

Loading stream...

(vianews) - shares of esi group (cac 40: esi.pa) jumped by a staggering 34.02% in 21 sessions from €77.6 to €104.00 at 14:53 est on friday, following the last session's upward trend. cac 40 is rising 0.67% to €7,497.02, following the last session's upward trend.

esi group's last close was €100.50, 25% higher than its 52-week high of €80.40.

about esi group

esi group sa, together with its subsidiaries, designs, develops, and distributes virtual prototyping software solutions in europe, the middle east, africa, the asia pacific, and the americas. the company offers vibro-acoustics, which allows engineers to perform accurate predictive noise and vibration design assessments early in the design cycle; virtual performance solutions; and virtual seat solutions. it also provides simulationx, a single platform for modeling, simulating, and analyzing technical systems; sysweld, which enables the designers and process planners to virtually manufacture, assemble, and test physically realistic virtual assemblies; systus, which offers a complete resolution to analysis challenges in mechanics, heat transfer, and electrotechnics; pam-stamp that provides sheet metal forming solutions; interior solutions; pam-composites; ic.ido, a virtual reality engineering software; and procast, which offers casting solutions, such as die casting, sand casting, and investment casting. in addition, the company offers consulting, technical support and assistance, and training services. it serves aerospace, defense, naval, automotive and land transport, energy, ground transportation, heavy machinery industries. the company was founded in 1973 and is headquartered in rungis, france.

earnings per share

as for profitability, esi group has a trailing twelve months eps of €2.89.

pe ratio

esi group has a trailing twelve months price to earnings ratio of 35.99. meaning, the purchaser of the share is investing €35.99 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.98%.

revenue growth

year-on-year quarterly revenue growth declined by 5.8%, now sitting on 133.92m for the twelve trailing months.

moving average

esi group's value is way higher than its 50-day moving average of €76.66 and way above its 200-day moving average of €73.21.

volatility

esi group's last week, last month's, and last quarter's current intraday variation average was 5.13%, 1.50%, and 1.74%.

esi group's highest amplitude of average volatility was 5.57% (last week), 2.67% (last month), and 1.74% (last quarter).

more news about esi group (esi.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com